PROBeX: Obtaining Medical History SOP (1289)

Citation: NIH R01AI114304. 2020. James C.M. Brust, MD., Graeme Meintjes, MBChB, PhD., Francesca Conradie, MBChB., Neel Gandhi, MD., Barry Kreiswirth, PhD., Gary Maartens, MBChB., Iqbal Master, MBChB., Koleka Milsana, MBChB, MMedPath., Sean Wasserman, MBChB., Julian te Riele, MBChB., Sweetness Siwendu, MBChB., John Black, MBChB., Helen McIlleron, MBChB; Chenshu Zhang, PhD; Barun Mathema, PhD; Elin Svensson, PhD. Albert Einstein College of Medicine, University of Cape Town, Witwatersrand University, Emory University, Center for Discovery and Innovation-Hackensack Meridian Health.

Study Description: Bedaquiline is the first new TB drug to receive FDA approval in 40 years. Major questions remain, however, concerning bedaquiline’s safety, mechanisms of resistance and drug-drug interactions with antiretroviral therapy. This study gathers clinical, microbiologic, and pharmacokinetic data in a highly drug-resistant patient population receiving bedaquiline that could benefit from the medication, but which has largely been excluded from clinical trials.

Document Type(s): SOP
Study Method(s): Quantitative Clinical
Geography: International
Study Year: 2020

Please complete the form below to download this resource

This field is for validation purposes and should be left unchanged.

This information is for internal data collection within Emory's Center for AIDS Research (CFAR) only. Any identifying information will not be shared externally.

Thank you to our contributing institutions